| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10940847 | Immunobiology | 2015 | 6 Pages |
Abstract
- C3 glomerulopathy (C3G) defines a group of untreatable ultra-rare renal diseases.
- C3G is caused by dysregulation of the alternative complement pathway.
- Nearly half of C3G patients progress to end stage renal failure within 10 years.
- Cp40, a compstatin analog, inhibits complement by binding to C3 and C3b.
- Cp40 may offer a novel and promising therapeutic option to C3G patients.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Yuzhou Zhang, Dingwu Shao, Daniel Ricklin, Brieanna M. Hilkin, Carla M. Nester, John D. Lambris, Richard J.H. Smith,